Infective endocarditis caused by vancomycin-resistant Enterococcus spp. (VRE-IE) is a distinct clinical situation in which standard vancomycin-based therapy is not applicable, requiring a targeted combination approach.
This protocol applies to patients with infective endocarditis in whom the causative pathogen is identified as vancomycin-resistant Enterococcus spp. — a finding that defines the treatment pathway and excludes vancomycin from the regimen.
Recommended treatment involves daptomycin used in combination with either a beta-lactam agent or fosfomycin. The specific agents, doses, routes, and duration that constitute the complete regimen are detailed in the full structured protocol.
Complete regimen available in the protocol below ↓DOI: 10.1093/eurheartj/ehad193
In patients with IE due to vancomycin-resistant Enterococcus spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or ceftaroline) or fosfomycin is recommended using the following doses:
View source ↗